Pabrinex shortage and guidance on alternatives
Pabrinex IV will be out of stock from July/ August 2024 until September 2025, due to supply issues relating to manufacturing regulations issued by the EU. Pabrinex IM will be permanently discontinued from December 2024. Pabrinex is only used in the UK, with thiamine IV/ IM being routinely used globally.
It is important to note if a Patient Group Direction (PGD) is being used (often used in community setting), only licensed products can be used in this setting. Therefore IM Pabrinex should be conserved for this purpose.
The following has been published online by the DHSC Specialist Pharmacy Service.
Joanna Henry, Gastroenterology Directorate Pharmacist, Liverpool University Hospitals NHS Trust
Sital Shah, Chair British Hepatology Pharmacy Group , Consultant Pharmacist, King’s College Hospital, London
BSG Inflammatory Bowel Disease Surveillance Guideline 2025
Our newly updated guideline for colorectal surveillance for patients with IBD is now available, providing a comprehensive road map for evidence-based, expert management of the whole pathway to try and prevent or detect bowel cancer early for this higher risk patient group.
BSG San Diego Travelling Fellowship Report by Amy Johnson
I am incredibly grateful to the Liver Section for awarding me this travelling fellowship. My time in San Diego was immensely beneficial for my career development, offering both educational and networking opportunities that I will build upon for years to come.
BSG San Diego Travelling Fellowship Report by Wenhao Li
I am writing to thank the BSG for providing financial support in order for me to attend MetALD meeting, AASLD meeting followed by a short stay with Prof Rohit Loomba’s team at UCSD.